SCHEMBL593284

SCHEMBL593284

Cc1ccccc1CN1CCNCC1

nearest known ligand 0.96

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.96
KMT2A Q03164 4/20 0.66
CYP2A13 Q16696 1/20 0.64
ACHE P22303 1/20 0.62
SIGMAR1 Q99720 1/20 0.56
MEN1 O00255 3/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KDM4E B2RXH2 5/20 0.54
ALDH1A1 P00352 4/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
MAPT P10636 1/20 0.51
ADRB1 P08588 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
GAA P10253 1/20 0.49
ATM Q13315 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GBA1 P04062 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2924720 0.98 LMNA (1.00) LMNAKMT2ACYP2A13ACHESIGMAR1
Hydrochloric Acid SCHEMBL7417639 0.98 LMNA (1.00) LMNAKMT2ACYP2A13ACHESIGMAR1
SCHEMBL29863134 0.93 LMNA (0.84) LMNAKMT2ACYP2A13ACHESIGMAR1
SCHEMBL14818737 0.93 LMNA (0.84) LMNAKMT2ACYP2A13ACHESIGMAR1
SCHEMBL3962172 0.86 LMNA (0.73) LMNAKMT2ACYP2A13ACHESIGMAR1
SCHEMBL29168432 0.85 LMNA (0.71) LMNAKMT2ACYP2A13ACHESIGMAR1
SCHEMBL30135292 0.82 LMNA (0.68) LMNAKMT2ACYP2A13ACHEMEN1
SCHEMBL329437 0.82 KMT2A (0.72) LMNAKMT2ACYP2A13ACHEMEN1
SCHEMBL14939663 0.81 LMNA (0.67) LMNAKMT2ASIGMAR1SLC6A2SLC6A4
SCHEMBL2493857 0.81 LMNA (0.66) LMNAKMT2ACYP2A13ACHESIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116496272-B 7-Benzyl piperazinyl-9-allyl dehydropeganine derivative and preparation method and application thereof 延安大学 2024-08-13 CN claimed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 US claimed
CN-116496272-A 7-benzyl piperazinyl-9-allyl dehydropeganine derivative and preparation method and application thereof 延安大学 2023-07-28 CN claimed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 US claimed
CN-109232576-B 7-substituted desoxypeganone base and preparation method and application thereof 信阳师范学院 2020-07-17 CN claimed
US-20200060997-A1 TARR Receptor Agonists for Sexual Dysfunction JOHN MCCOY 2020-02-27 US claimed
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 EP claimed
WO-2026106796-A1 SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS FOLLEA INTERNATIONAL (US) 2026-05-21 WO disclosed
EP-3841085-B1 NBOME TEST UNIV SYDNEY TECHNOLOGY (AU) 2026-05-06 EP disclosed
US-20260041652-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA FOLLEA INT (US) 2026-02-12 US disclosed
EP-0279681-A2 Saturated heterocyclic carboxamide derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-24 EP disclosed
EP-0252670-A2 2-Substituted alkoxy-3-substituted-pyrazines TOYO JOZO KABUSHIKI KAISHA (JP) 1988-01-13 EP disclosed
US-4692448-A ANTIALLERGENS AND ANTIINFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1987-09-08 US disclosed
EP-0182349-A1 Bis(arylpiperazinyl)sulfur compounds Boehringer Ingelheim Pharmaceuticals Inc. (US) 1986-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R LMNA 1739/4885KMT2A 2733/4885CYP2A13 274/4885
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ LMNA 2327/4885KMT2A 1734/4885CYP2A13 3044/4885
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof HBZ, ZFX, WIZ LMNA 2327/4885KMT2A 1734/4885CYP2A13 3044/4885
US-20260041652-A1 SYSTEM AND METHOD FOR PREVENTING ALOPECIA DYRK4, DYRK2, STRA6 LMNA 2196/4885KMT2A 3717/4885CYP2A13 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.